identifi
malaria
antigen
vaccin
develop
select
ahel
coil
coil
domain
protein
predict
present
parasit
erythrocyt
stage
correspond
synthet
peptid
expect
mimic
structur
nativ
epitop
inde
chemic
synthes
peptid
specif
recogn
human
immun
sera
though
variou
preval
peptid
specif
antibodi
obtain
affinitypurif
malaria
immun
sera
immun
mice
antibodi
show
signific
cross
reaction
ie
specif
origin
peptid
react
nativ
parasit
protein
infect
erythrocyt
sever
activ
inhibit
vitro
parasit
growth
circular
dichroism
studi
indic
select
peptid
assum
partial
high
ahel
content
thu
demonstr
bioinformaticschem
synthesi
approach
describ
lead
rapid
identif
molecul
target
biolog
activ
antibodi
thu
identifi
suitabl
vaccin
candid
strategi
principl
extend
vaccin
discoveri
wide
rang
pathogen
human
plasmodium
falciparum
pf
infect
dramat
public
health
problem
today
approxim
forti
percent
world
popul
risk
malaria
malaria
caus
million
acut
clinic
case
least
one
million
death
annual
nineti
percent
malaria
death
occur
subsaharan
african
countri
mostli
among
young
children
pregnant
women
http
rbmwhoint
thu
urgent
need
malaria
vaccin
howev
vaccin
discoveri
gener
particularli
malaria
still
empir
process
fact
protect
antigen
bear
structur
physicochem
sequencerel
characterist
would
allow
identif
protect
humor
respons
recogn
characterist
antigen
antigenicityimmunogen
access
addit
lack
surrog
marker
protect
render
vaccin
discoveri
process
difficult
time
consum
henc
spite
constant
impress
progress
molecular
biolog
techniqu
antigen
identif
express
vaccin
discoveri
still
laborintens
make
approach
fastidi
costli
poorli
adapt
highthroughput
screen
proper
protein
fold
solubl
remain
limit
numer
case
thu
overcom
bottleneck
manufactur
identif
fragmentsprotein
possibl
target
protect
immun
respons
still
constitut
scientif
technic
challeng
address
challeng
combin
bioinformat
chemic
peptid
synthesi
function
protect
assay
focus
search
ahel
coil
coil
motif
gener
exhibit
fold
problem
target
effect
antibodi
sever
current
malaria
vaccin
candid
eg
pathogen
anoth
lead
malaria
vaccin
also
contain
predict
ahel
coil
coil
region
unpublish
result
choic
base
follow
consider
first
ahel
coil
coil
motif
bear
characterist
seven
amino
acid
residu
repeat
abcdefg
n
hydrophob
residu
locat
posit
hydrophil
residu
gener
elsewher
motif
easili
identifi
bioinformat
analysi
secondli
import
known
characterist
ahel
coil
coil
domain
taken
separ
whole
protein
frequent
readili
fold
stabl
oligomer
structur
thirdli
reason
ahel
coil
coil
fragment
frequent
recogn
conform
depend
antibodi
similarli
elicit
antibodi
reactiv
structur
nativ
epitop
addit
domain
short
residu
rapidli
produc
chemic
synthesi
furthermor
antibodi
antiparasit
biolog
activ
design
correspond
protein
fragment
potenti
novel
vaccin
candid
develop
assess
focu
pf
parasit
erythrocyt
stage
target
protect
antibodi
describ
straightforward
rapid
procedur
base
bioinformat
analysi
ahel
coiledcoil
motif
peptid
synthesi
screen
pf
genom
use
gener
sequenc
profil
identifi
sever
hundr
protein
contain
put
ahel
coil
coil
motif
proteom
transcriptom
data
assess
molecul
express
pf
parasit
erythrocyt
stage
combin
analysisassess
identifi
segment
associ
stage
display
put
ahel
coil
coil
motif
high
probabl
score
tabl
ahel
coil
coil
fragment
gener
amino
acid
long
present
either
protein
differ
one
chemic
synthes
hplc
purifi
among
longer
peptid
amino
acid
contain
one
ahel
coil
coil
domain
also
synthes
antigen
tabl
select
antigen
test
elisa
assay
reactiv
three
panel
sera
obtain
adult
donor
burkina
faso
tanzania
colombia
respect
surpris
ahel
coil
coil
fragment
antigen
though
preval
respond
vari
greatli
tabl
manner
protein
identifi
whose
length
vari
amino
acid
twentyon
peptid
highest
preval
respond
elisa
mean
od
valu
select
studi
variat
recognit
among
three
panel
sera
may
due
differ
genet
background
host
parasit
like
distinct
malaria
transmiss
condit
three
region
high
level
recognit
ahel
coil
coil
motif
may
explain
fact
taken
separ
whole
protein
fragment
readili
fold
stabl
structur
aqueou
solut
inde
circular
dichroism
cd
studi
select
peptid
associ
biolog
activ
tabl
indic
predominantli
assum
ahel
conform
water
peptid
figur
exhibit
cd
pattern
characterist
high
ahel
content
wherea
remain
peptid
show
cd
profil
similar
shown
peptid
figur
intermedi
shown
figur
characterist
partial
ahel
organ
analyz
size
exclus
chromatographi
fplc
column
peptid
present
elut
profil
exhibit
chymotrypsin
ribonucleas
mw
respect
cd
size
exclus
chromatographi
result
suggest
peptid
adopt
ahel
coiledcoil
structur
need
unambigu
ascertain
nmr
ultracentrifug
studi
test
biolog
activ
peptidespecif
antibodi
latter
purifi
affin
chromatographi
use
three
serum
pool
obtain
papua
new
guinean
adult
serum
pool
first
test
elisa
assay
peptid
antigen
tabl
peptidespecif
antibodi
purifi
posit
serum
pool
test
elisa
antibodi
react
parasit
nativ
protein
infect
red
blood
cell
shown
ifat
figur
tabl
reactiv
restrict
blood
stage
sinc
antibodi
react
sporozoit
stage
data
shown
reactiv
also
peptidespecif
shown
ifat
competit
assay
correspond
peptid
figur
specif
antibodi
obtain
investig
detail
particularli
sinc
sever
peptid
contain
glutam
acid
glu
rich
sequenc
known
gener
cross
reactiv
among
sever
malari
glurich
protein
crossreact
systemat
investig
use
affinitypurifi
antibodi
peptid
result
show
thatwith
exceptionseach
antibodi
preferenti
recogn
peptid
antibodi
affinitypurifi
ie
specif
correspond
peptid
tabl
determin
nonspecif
antibodi
bind
solid
phaseadsorb
antigen
could
respons
rare
crossreact
detect
elisa
competit
assay
perform
end
bind
antibodi
solid
phaseadsorb
antigen
compet
increas
concentr
homolog
crossreact
peptid
homolog
peptid
compet
best
wherea
peptid
sequenc
similar
figur
much
higher
concentr
figur
includ
shorter
glurich
peptid
deriv
cterminu
peptid
figur
final
pattern
recognit
peptid
variou
sera
test
differ
markedli
one
data
shown
confirm
result
ie
specif
antibodi
correspond
peptid
antibodi
correspond
select
peptid
test
direct
cellmedi
antiparasit
activ
clinic
experi
shown
antibodydepend
cellmedi
inhibit
adci
p
falciparum
malaria
repres
one
mechan
control
parasitemia
therebi
clinic
manifest
human
twelv
peptidespecif
antibodi
prove
abl
induc
strong
intermedi
lower
monocytedepend
parasit
kill
tabl
wherea
absenc
monocyt
direct
effect
antibodi
parasit
growth
observ
effect
rang
observ
antibodi
african
adult
highest
natur
protect
known
malaria
therefor
peptidespecif
human
affinitypurifi
antibodi
function
effect
shown
abil
react
parasit
protein
inhibit
parasit
growth
thu
vitro
function
assay
show
peptidespecif
antibodi
elicit
natur
exposur
parasit
induc
protect
mechan
effect
malaria
sixteen
peptid
twelv
target
adci
posit
antibodi
four
controlswer
use
immun
mice
tabl
eleven
elicit
intermedi
high
antibodi
respons
four
also
recogn
parasit
protein
infect
erythrocyt
determin
ifat
figur
tabl
seen
human
antibodi
recognit
restrict
blood
stage
sinc
sporozoit
neg
ifat
assay
data
shown
ifat
competit
assay
correspond
peptid
figur
antipeptid
mous
antibodi
posit
ifat
also
specif
homolog
peptid
sequenc
relat
peptid
tabl
thu
peptid
chosen
propens
form
ahel
coil
coil
induc
product
antibodi
recogn
epitop
present
nativ
protein
improv
immunogen
structur
specif
remain
peptid
might
achiev
futur
short
elong
nand
ctermin
end
b
stabil
ahelix
suggest
cooper
et
al
lu
hodg
andor
c
use
adjuv
genet
polymorph
current
vaccin
candid
major
limit
vaccin
develop
howev
avail
genotyp
studi
peptid
sequenc
parasit
isol
worldwid
origin
indic
limit
polymorph
plasmodb
unpublish
sequenc
data
peptid
dna
sequenc
show
delet
one
entir
heptad
repeat
shorter
region
still
preserv
potenti
ahel
coil
coil
format
regard
structur
featur
cellular
locat
predict
protein
correspond
peptid
select
adci
assay
tabl
protein
contain
pentapeptid
conform
pexel
consensu
none
posit
within
amino
acid
sequenc
conform
locat
known
activ
pexel
motif
see
materi
method
membran
segment
none
gpi
anchor
one
protein
contain
signal
sequenc
fourteen
protein
predict
cytoplasm
one
nucleu
one
mitochondria
one
peroxysom
tabl
predict
subcellular
local
protein
taken
caution
gene
annot
constantli
updat
andor
protein
traffick
parasit
complex
fulli
elucid
investig
requir
determin
actual
local
correspond
antigen
predict
local
priori
surpris
molecul
abl
trigger
adci
activ
howev
recent
studi
shown
addit
merozoit
surfac
protein
solubl
protein
releas
time
schizont
ruptur
equal
effect
trigger
adci
provid
defin
least
two
epitop
case
ahel
coil
coil
heptad
repeat
therefor
molecul
express
transmembran
domain
export
parasit
host
cell
membran
well
molecul
present
cytoplasm
matur
schizont
releas
burst
schizont
trigger
antibodi
crosslink
fcc
receptor
monocyt
achiev
pf
parasit
kill
conclus
approach
combin
genomewid
search
bioinformat
ahel
coil
coil
protein
motif
chemic
synthesi
lead
rapid
identif
develop
new
malaria
vaccin
candid
fact
approach
straightforward
easi
scale
vaccin
formul
may
compris
mixtur
peptid
singl
construct
made
sever
epitop
principl
strategi
extend
discoveri
protein
vaccin
candid
complex
pathogen
pf
genom
use
bioinformat
analysi
gener
sequenc
profil
method
pftool
packag
use
search
short
ahel
coil
coil
domain
coil
coil
profil
construct
use
align
sever
amino
acid
sequenc
correspond
known
coil
coil
domain
two
profil
contain
four
five
heptad
repeat
use
analysi
cutoff
level
profil
chosen
test
perform
sequenc
databas
protein
known
structur
subsequ
coil
coil
figur
immunofluoresc
microscopi
analysi
pf
parasit
peptid
specif
antibodi
acetonemethanolfix
schizont
merozoit
react
human
peptid
specif
affin
purifi
antibodi
obtain
peptid
tabl
b
sera
mice
immun
peptid
tabl
grey
bright
field
imag
blue
stain
indic
dapi
nuclear
stain
schizont
stage
parasit
red
stain
show
label
peptid
specif
antibodi
antihuman
antimous
igg
specif
antibodi
merg
pictur
overlay
blue
red
fluoresc
channel
region
select
approach
test
manual
presenc
characterist
heptad
repeat
protein
also
analyz
coil
program
select
ahel
coil
coil
contain
protein
test
possibl
surfac
locat
gpi
anchor
use
follow
program
identif
potenti
signal
peptid
secretomep
signalp
http
www
cbsdtudkservic
transmembran
span
region
tmpred
http
wwwchembnetorgsoftwaretmpr
formhtml
tmhmm
http
wwwcbsdtudkservic
tmhmm
gpianchor
protein
http
mendel
impunivieacatsatgpigpiserverhtml
predict
subcellular
local
ptarget
http
bioinformat
albanyedu
ptarget
identifi
pexellik
motif
sequenc
select
protein
use
follow
pattern
deq
repres
combin
pexel
pattern
indic
recent
paper
presenc
identifi
protein
asexu
erythrocyt
stage
also
check
use
publish
data
transcriptom
proteom
stage
develop
p
falciparum
wwwplasmodborg
peptid
synthes
advanc
chemtech
hatley
st
georg
uk
ac
omega
multi
channel
synthes
appli
biosystem
synthes
foster
citi
ca
use
solidphas
fmoc
chemistri
crude
peptid
purifi
rphplc
prepar
column
analyz
mass
spectrometri
malditof
appli
biosystem
foster
citi
ca
chemic
solvent
use
peptid
synthesi
purchas
fluka
buch
switzerland
novabiochem
laufelfing
switzerland
circular
dichroism
cd
spectra
peptid
record
jasco
spectromet
jasco
corpor
tokyo
japan
equip
temperatur
control
cm
path
length
cuvett
measur
made
water
ph
peptid
concentr
mgml
sera
burkina
faso
collect
villag
goundri
locat
central
mossi
plateau
km
north
capit
ouagadoug
provinc
oubritenga
climat
characterist
area
sudanes
savannah
dri
season
novemb
may
raini
season
june
octob
malaria
transmiss
high
raini
season
markedli
season
ethic
clearanc
obtain
ministri
health
burkina
faso
obtain
inform
consent
parent
caretak
heparin
venou
blood
sampl
collect
crosssect
survey
malaria
low
transmiss
season
tanzanian
sera
came
largescal
commun
base
studi
undertaken
kikwalila
villag
kilombero
district
morogoro
region
blood
sampl
adult
year
taken
finger
prick
serum
kept
use
research
ethic
clearanc
studi
obtain
tanzanian
commiss
scienc
technolog
colombian
sera
collect
buenaventura
main
port
colombian
pacif
coast
human
inform
consent
cross
section
survey
carri
februari
may
within
framework
project
support
colombian
research
council
colciencia
area
unstabl
transmiss
p
falciparum
p
vivax
malaria
ethic
clearanc
draw
blood
human
volunt
human
purifi
antibodi
use
mgml
ifat
perform
ring
stage
vall
blood
taken
venipunctur
tube
contain
edta
sera
fraction
store
frozen
use
sera
adult
papua
new
guinea
png
pool
affin
purif
collect
maprik
district
east
sepik
provinc
cross
section
survey
juli
within
framework
malaria
vaccin
epidemiolog
evalu
project
mveep
support
unit
state
agenc
intern
develop
area
highli
endem
malaria
ethic
clearanc
mveep
obtain
png
medic
research
advisori
committe
blood
taken
venipunctur
tube
contain
edta
pool
immun
african
globulin
piag
use
adci
prepar
immun
individu
live
endem
area
neg
control
igg
nigg
obtain
pool
french
adult
donor
histori
malaria
briefli
igg
fraction
posit
neg
control
purifi
use
size
exclus
trisacrylh
pall
bioseprah
pall
life
scienc
ny
column
follow
ionic
exchang
deae
ceram
hyperdh
f
column
pall
bioseprah
purifi
igg
extens
dialyz
rpmi
kept
use
mice
inject
time
mg
indic
peptid
montanid
isa
base
tail
day
bleed
perform
day
second
third
immun
elisa
perform
accord
lopez
et
al
anti
human
iggor
anti
mous
igg
conjug
alkalin
phosphatas
use
sigma
st
loui
mo
second
antibodi
individu
human
sera
adult
donor
burkina
faso
tanzania
colombia
respect
use
dilut
serum
consid
posit
optic
densiti
od
read
higher
mean
od
standard
deviat
sd
neg
control
individu
serum
sampl
swiss
donor
od
ratio
mean
duplic
experiment
valu
mean
od
neg
control
higher
mous
sera
end
point
valu
determin
last
dilut
mean
od
standard
deviat
sd
neg
control
non
immun
sera
elisa
competit
assay
perform
incub
either
select
human
affinitypurifi
antibodi
antibodi
elicit
mice
togeth
antigen
indic
rang
concentr
minut
room
temperatur
prior
addit
elisa
peptideco
plate
well
antigensepharos
conjug
prepar
mg
antigen
dissolv
ml
coupl
buffer
nahco
contain
nacl
ph
cnbrsepharos
amersham
bioscienc
ab
uppsala
sweden
activ
swell
mm
hcl
wash
coupl
buffer
antigen
solut
ad
gel
mixtur
stir
rt
coupl
reaction
excess
antigen
wash
away
coupl
buffer
unreact
activ
group
block
treatment
ethanolamin
ph
min
rt
gel
wash
sodium
acet
buffer
ph
follow
coupl
buffer
antigensepharos
bead
either
use
store
pb
contain
mm
azid
isol
specif
antibodi
pool
human
serum
dilut
five
time
pb
contain
sodium
chlorid
mix
antigensepharos
conjug
mixtur
stir
gentli
wheel
centrifug
supernat
collect
store
use
antigensepharos
bead
wash
ml
trizma
base
tri
mm
contain
nacl
ph
ml
tri
mm
ph
elut
bound
antibodi
achiev
glycin
ph
fraction
obtain
instantli
neutral
tri
ph
dialyz
phosphat
buffer
ph
antibodi
concentr
determin
absorb
solut
nm
slide
coat
pf
sporozoit
dri
rt
minut
fix
aceton
minut
wash
time
tween
dri
care
block
ml
well
bovin
serum
albumin
bsa
minut
rt
slide
coat
pf
merozoit
fix
aceton
minut
dri
rt
appropri
antibodi
serum
dilut
prepar
bsa
distribut
mlwell
incub
rt
humid
chamber
wash
goat
antihuman
goat
antimous
polyval
immunoglobulin
conjug
molecular
probe
dilut
bsa
antihuman
igg
fc
specif
fitc
conjug
sigma
dilut
evan
blue
solut
ad
mlslide
incub
rt
humid
chamber
dark
slide
wash
cover
glycerol
seal
read
use
fluoresc
microscop
leica
dmirb
uganda
palo
alto
strain
fupc
cultur
supplement
albumax
gibcobrlinvitrogen
san
diego
ca
adci
assay
blood
stage
parasit
cultur
synchron
least
two
success
sorbitol
treatment
follow
matur
h
floatat
porcin
skin
gelatin
type
sigma
blood
monocyt
mn
prepar
cytapheresi
sampl
obtain
healthi
blood
donor
previou
histori
malaria
lecourb
blood
bank
pari
franc
peripher
blood
mononuclear
cell
pbmc
separ
ficol
densiti
gradient
j
prep
techgen
le
uli
franc
wash
ca
mg
free
hbss
buffer
mm
hepe
gibcobrlinvitrogen
cell
distribut
polystyren
flatbottom
cultur
plate
tpp
trasadingen
switzerland
adher
mn
select
incub
h
humidifi
co
atmospher
adher
cell
obtain
manner
mn
estim
nonspecif
esteras
test
anaphtyl
acet
esteras
sigma
mn
donor
test
prior
adci
assay
without
direct
inhibitori
effect
use
assay
well
contain
mn
purifi
describ
ml
asynchron
parasit
cultur
parasitemia
hematocrit
ad
well
supplement
test
control
antibodi
ab
total
volum
adjust
ml
cultur
medium
h
h
ml
cultur
medium
ad
well
h
adci
assay
stop
final
parasitemia
determin
light
microscopi
giemsastain
smear
count
red
blood
cell
ab
test
duplic
well
includ
follow
control
nonspecif
monocyt
inhibit
mnparasit
mnniggparasit
direct
inhibit
control
test
igg
niggparasit
test
absparasit
piag
nigg
use
final
concentr
mgml
posit
neg
control
respect
immunopurifi
test
ab
use
mgml
specif
growth
inhibitori
index
sgi
consid
parasit
growth
inhibit
due
effect
test
ab
cooper
mn
calcul
follow
sgi
parasitemia
mn
test
ab
parasitemia
test
ab
parasitemia
mn
nigg
parasitemia
nigg
figur
cd
spectra
peptid
found
mb
tif
figur
elisa
inhibit
assay
use
antihuman
peptid
specif
antibodi
bind
peptid
specif
antibodi
peptid
absorb
elisa
plate
inhibit
incub
specif
antibodi
mgml
peptid
peptid
respect
see
materi
method
peptid
share
nnm
mnn
sequenc
similar
peptid
exhibit
appar
sequenc
similar
tabl
structur
featur
cellular
locat
predict
protein
contain
peptid
whose
specif
antibodi
test
adci
tabl
found
mb
doc
